# Vaccination Plus Ontak in Patients With Metastatic Melanoma

> **NCT00515528** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 17 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** 4-peptide melanoma vaccine
- **DRUG:** Ontak

## Key facts

- **NCT ID:** NCT00515528
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04-23
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The immune monitoring data failed to demonstrate an improvement in any biologic endpoint with denileukin diftitox.
- **Last updated:** 2021-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515528, "Vaccination Plus Ontak in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00515528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*